Disposition and metabolism of [3H]pseudomorphine in the rat by Misra, A. L. & Mule', S. J.
Biochemical Pharmacology, Vol. 21, pp. 103-107. Pergamon Press, 1972. Printed in Great Britain 
DISPOSITION AND METABOLISM OF 
[3HlPSEUDOMORPHINE IN THE RAT 
A. L. MISRA* and S. J. MULE’* 
Department of Pharmacology, University of Michigan, Medical School and New York 
State NACC, Testing and Research Laboratory, Brooklyn, N.Y. 11217, U.S.A. 
(Received 7 May 1971; accepted 23 July 1971) 
Abstract-[3H]pseudomorphine (3H-PM) was prepared by the oxidation of [3H]mor- 
phine. A method for the estimation of 3H-PM in biological materials was developed 
with a minima1 sensitivity of 2.5 ng/ml of biologic material. Following the subcutaneous 
injection of 3H-PM (10 mg/kg as free base) in rats, the levels of 3H-PM in brain and 
spinal cord over a 2-hr period ranged between 46 to 17.9 rig/g and 24 to 76.5 rig/g,, 
respectively. No detectable levels of 3H-PM were present at 4 hr in the CNS. Peak 
plasma levels occurred at 30 min (501 ng/ml) and then fell rapidly with no detectable 
amounts present at 4 hr. About 78.2 per cent of the administered 3H-PM was accounted 
for in the urine and feces after 48 hr. Conjugated pseudomorphine was not detected in 
biological material, and direct chromatography of urine provided evidence for the 
presence of only free 3H-PM. The existence of a polar metabolite, however, cannot be 
precluded. Studies on rat brain extracts following the administration of [jH]morphine 
(10 mg/kg as free base) provided no evidence for the formation of pseudomorphine as 
an oxidative metabolite of morphine in vivo. 
PSEUDOMORPHINE (2: 2’-bimorphine), as an oxidation product of morphine,lV3 is of 
special interest because of a possible involvement in the agonistic action of morphine 
or the development of tolerance and/or physical dependence following chronic 
administration of morphine. This view has not received wide acceptance,4s5 primarily 
because pseudomorphine has not been identified as a metabolite in vivo of morphine 
in biological materials, although Hosoya and Brody,6 utilizing rat tissue homogenates 
in the presence of cytochrome c, apparently demonstrated the oxidation of morphine 
to pseudomorphine in vitro. 
The known physicochemical characteristics of pseudomorphine,’ i.e. very limited 
solubility in saline, biological fluids and common organic solvents, difficulty of 
separation from proteins and formation of an insoluble salt with trichloroacetic acid, 
have interfered with the development of a suitable, sensitive analytical method for 
the extraction and estimation of this compound from biological materials. 
This communication describes the preparation, disposition and biotransformation 
of [3H]pseudomorphine (3H-PM) in the rat. The method described for the estimation 
of [3H]pseudomorphine from biological materials has been used to ascertain whether 
this compound is a metabolite of [3H]morphine in the CNS of rats. 
MATERIALS AND METHODS 
Preparation of tritium-labeled pseudomorphine (3H-Ph4). [3H]Pseudomorphine was 
prepared by the oxidation of [3H]morphine (50 mg) by a microscale adaptation of the 
* Present address: New York State NACC, Testing and Research Laboratory, Brooklyn, New 
York 11217. 
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procedure of Bentley and Dykes.’ The colorless powdery material (yield, 30 mg, 
m.p. over 300”) had a specific activity of 4.7 pc/mg. Paper chromatography with the 
solvent n-butanol-acetic acid-water (4: 1: 5, by vol.) and radioscanning of chromato- 
gram showed a single peak of radioactivity coincidental to authentic pseudomorphine 
(A, 0.1). No [3H]morphine was present in the product (R, O-4). 
Estimation of 3H-PM from biological materials. A 2-ml sample of biological fluid 
or tissue (10% homogenate in 0.5 N HCl) was mixed with 2 ml of non-labeled 
pseudomorphine solution (200 p/ml as free base) as carrier in a 40.ml centrifuge 
tube. The solution was adjusted to pH 10 with diluted NaOH and saturated with 1.5 g 
of NaCl. One ml of phosphate buffer* pH IO.4 and 15 ml of a 30 % solution of n-amyl 
alcohol in ethylene dichloride were added and the mixture shaken for 40 min at 300 
oscillations/min with an International shaker machine. The samples were centrifuged 
for 5 min at 1500 g and lo-ml aliquots of the upper organic phase were transferred to 
counting vials and evaporated at 65” on a Fisher slide warmer. The residues were 
dissolved in O-8 ml of n-amyl alcohol and 10 ml of toluene phosphor solution.7 All 
samples in duplicate were counted in a Tri-Carb liquid scintillation spectrometer. 
Background samples, known concentrations of 3H-PM, and internal standards of 
[3H]toluene were run concurrently with the unknown samples to provide a check on 
the extraction and counting efficiency. 
Conjugated 3H-PM was determined by autoclaving each sample with 0.1 volume of 
cont. HCl for 25 min at 18-20 lb pressure, adjusting the pH to 10 with diluted NaOH 
and extracting the samples as described above. 
Recoveries of 50-1000 ng of 3H-PM added to rat brain and plasma and carried 
through the described extraction procedure were 95 f 5% (S.E.M.). The minimal 
sensitivity of detection of 3H-PM by this method was 5 ng (2.5 ng/ml). 
Disposition studies. 3H-PM was injected subcutaneously at a dose of 10 mg/kgS to 
male Sprague-Dawley rats weighing 200-250 g. Prior to sacrifice, the animals were 
lightly anesthetized with ether and blood obtained by cardiac puncture. The blood 
was centrifuged (in 15-ml potassium-oxalated centrifuge tubes) for 40 min at 1500 g 
to obtain plasma which was suitably diluted and analyzed as described. At intervals 
of 30 min to 4 hr after administration of drug, the animals were sacrificed by a light 
blow on the head and immediate incision of the heart. The internal carotids were 
catheterized and the brain perfused with 8-10 ml of physiological saline. Brain and 
spinal cord were removed, weighed and homogenized in sufficient 0.5 N HCl to 
provide a final volume of 5 ml. Two-ml samples in duplicate were then analyzed as 
described previously. 
Urinary andfecai studies. 3H-PM was injected subcutaneously at a dose of 10 mg/kg 
to male Sprague-Dawley rats. Urine and feces were collected for 48 hr in metabolism 
cages. The feces were homogenized with a known volume of O-5 N HCI and analyzed 
for free and conjugated 3H-PM as described. 
Chromatographic experiments. Descending paper chromatography of aliquots of 
urine after addition of non-radioactive pseudomorphine as carrier was performed on 
* Potassium phosphate buffer was prepared by dissolving 350 g anhydrous potassium dibasic 
phosphate (KJ-IPO,) and 50 g potassium tribasic phosphate &PO,) in 11. of double distilled water. 
t Toluene phosphor solution was prepared by dissolving 3 g of 2,5-diphenyloxazole (PPO) and 100 
mg of 1,4-bis-2-(5-phenyloxazole)-benzene (POPOP) in 1 1. of analytical grade toluene. 
$ J&PM injection solution was prepared as the tartrate salt with given dose calculated as the free 
base. 
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Whatman 3 MM paper using n-butanol-acetic acid-water (4: 1:2) as the solvent 
system. The chromatogram was observed with U.V. light and sprayed with the iodo- 
platinate reagent, and the remaining section scanned by eiution of strips with diluted 
hydrochloric acid and counting the radioactivity in the liquid scintillation counter. 
RESULTS 
Distribution of 3H-PM in the CNS and plasma of rats. It is evident from Table 1 
that the levels of free 3H-PM in the CNS at various time intervals were quite low with 
the maximum value occurring in brain at 30 min and no detectable amounts (c 5 ng) 
at 4 hr. In the spinal cord, the maximum ~on~n~ation of 3H-PM occurred at 2 hr 
(765 ng[g) with no detectable amounts (< 5 ng) at 30 min and 4 hr. 
TABLE 1. LEVERS OF FREE [3H~~~~~~~m (jH-PM) IN THE BRAIN, SPINAL CORD AND PLASMA OF 
RATS AT INTERVALS AFTER THE SUBCUTANEOUS INJECTION OF 10 rag/kg& Film BASE) 
Time after 
injection Brain 
Concentration of 3H-PM* 
(nglg or ml) 
Spinal cord Plasma B/Pt 
3omin 17.9 f o-3 M)s 501 f 21 @034 
:: 
46 f 1.5 24-O + 9-o 288 f 18 0.016 
5-9 f 0.4 765 i 14 203 f 35 0,029 
4hr ND ND ND 
* Duplicate determinations for free 3H-PM were performed on three to four rats per time interval. 
The values expressed as f S.E.M. 
t B/P, represents the ratio obtained by dividing the concentration in brain by the concentration in 
plasma at each time interval. 
$ ND, the drug was not detected at the stated time interval. 
Plasma levels of 3H-PM indicated rapid absorption of 3H-PM with a maximum 
level of 501 nglml at 30 min. The level of drug fell rapidly to 288 ng/ml at 1 hr, then 
remained relatively stable through 2 hr, with no detectable quantity (< 5 ng) at 4 hr. 
Brain to plasma ratios at 30 min, 1 and 2 hr were 0*034,0*016 and 0.029 respectively. 
Conjugated 3H-PM was not detected in the CNS or plasma at the various time 
intervals studied. 
Urinary and fecal excretion of 3H-PM. The data on percentage recovery of 3H-PM 
and total radioactivity in the urine and feces are summarized in Table 2. Conjugated 
3H-PM was not detected in the urine or feces. 
Metabolic studies. Direct chromatography in n-butanol-acetic acid-water (4: 1: 2) 
of a small aliquot of urine collected over a 48-hr period following the administration 
of 10 mg/kg of 3H-PM showed the presence of a single radioactive spot with Rz 0.17 
coincidental to authentic non-labeled pseudomorphine (R, 0*18). The presence of 
some radioactivity at the origin might suggest the existence of a polar metabolite of 
pseudomorphine. 
In another series of experiments, the brains of five male rats removed 60 min after 
a subcutaneous injection of ~iti~-labeled morphine (1Om~kg as free base) were 
106 A. L. MLLBA and S. J. MULE’ 
TILE 2. t.kNARY, FECAL EXCRETION OF FREE 3H-PM AND TOTAL RADIO- 
ACTIW 48 hr AFTBR THE S~BC~TANJ?O?JS AD~WISTRATION OF 10 mg/kg (AS 
FREE BASE) TO RAT?3 
Mean percentage recovery of 3H-PM* 







* Figures represent the mean percentage of the ad~nistered dose of 
3H-PM recovered from the urine and feces of five male rats. 
7 This was determined in duplicate by adding 0.2 ml of suitably diluted 
urine or feces to a scintillationcounting vial and mixing with 3 ml of absolute 
ethanol, and 6.8 ml of toluene phosphor solution. All sampleswerecorrected 
for quenching. 
pooled, homogenized in 1 N HCl containing non-labeled pseudomorphine, morphine 
and normorphine as carriers. The homogenates were extracted at pH 9 and as des- 
cribed and the pooled organic phase evaporated to dryness. Paper chromatography 
of the residue with n-butanol-acetic acid-water (4: 1: 5, by vol.) and radioscanning 
showed the presence of free morphine but no evidence for the formation of pseudo- 
morphine as a metabolite of morphine in the brain of rats. A conversion of 1% of 
morphine-3H present in rat brain 1 hr after injection to pseudomo~hine-3H would 
give rise to a con~ntration of about 3-O rig/g (about 20-30 ng in the pooled brain 
sample) of p~udomo~hine-3H in rat brain and would have been easily detected 
by our procedure. 
DISCUSSION 
This study demonstrates that pseudomorphine, unlike morphine, does not penetrate 
the blood-brain barrier to provide sufficient concentrations in the central nervous 
system of rats. The concentrations of morphine-N-methy114C in rat brain at the same 
dose level and by the same route of injection have been reported8 to be 324 and 285 
rig/g at 30 and 60 min respectively. Although, the method of anesthesia, technique of 
sacrifice of animals and perfusion of cerebral vascular system might alter the distri- 
bution of 3H-PM in brain tissue, our observation would agree with previous 
studiesg*lo which indicated that pseudomo~hine given orally or su~ut~~ously 
produced neither narcosis nor respiratory depression. Acute circulatory depression 
resulting chiefly from peripheral vasodilatation characterized by muscular weakness 
and some general depression have been observedIe with intravenous administration of 
pseudomorphine. 
Approximately 78.2 per cent of the administered dose of 3H-PM could be accounted 
for in urine and feces collected over a 48-hr period by our extraction procedure. 
Since almost the entire dose of 3H-PM was accounted for on the basis of data on 
total radioactivity, it would appear that a polar metabolite not extracted by our 
procedure might be present. Although acid hydrolysis of urine and chromatography 
studies indicated the absence of a glucuronide or ethereal sulfate conjugate of 3H-PM, 
this does not preclude the possibility of the presence of some other polar metabolite 
which may escape detection by methods used in this study. 
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The present study provided no evidence for the formation of 3H-PM as a metabolite 
of morphine in the brain of rats in uiuo and furnishes suggestive evidence that 3H-PM 
is probably not responsible for or associated with the agonistic actions of morphine, 
the phenomena of tolerance and/or physical dependence. 
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